| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5594410 | American Heart Journal | 2017 | 7 Pages |
Abstract
Compared with enalapril, sacubitril/valsartan reduced the risk of both the primary endpoint and a coronary composite outcome in PARADIGM-HF. Additional studies on the effect of sacubitril/valsartan on atherothrombotic outcomes in high-risk patients are merited.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Ulrik M. MD, PhD, Lars MD, DMSc, Søren L. MD, PhD, Pardeep S. MBChB, PhD, Jianjian MD, Martin P. MD, Adel R. PharmD, Jean L. MD, Victor C. MD, Karl MD, PhD, Michael R. MD, PhD, Scott D. MD, Milton MD, John J.V. MD,